$-0.14 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN)

April 17, 2018 - By Darrin Black

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment increased to 2.08 in Q4 2017. Its up 1.12, from 0.96 in 2017Q3. It improved, as 10 investors sold Achillion Pharmaceuticals, Inc. shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported.
Legal And General Grp Public Limited Com, a United Kingdom-based fund reported 46,345 shares. Manufacturers Life Ins Com The accumulated 94,043 shares. Ny State Common Retirement Fund owns 118,300 shares or 0% of their US portfolio. The California-based Clarivest Asset Mngmt Ltd Company has invested 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Stifel Fincl Corp stated it has 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Bancorporation Of Montreal Can reported 0% stake. Credit Suisse Ag accumulated 170,897 shares. Moreover, Citigroup Incorporated has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Glenmede Tru Na invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Millennium Limited Liability has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Texas-based Hbk Investments Lp has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). National Bank Of America Corp De holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 442,778 shares. Bb Biotech Ag has 0.1% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Eventide Asset Mgmt Ltd Liability Corporation stated it has 850,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 2,980 shares.

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.14 EPS on May, 3.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.17 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see -17.65 % EPS growth. The stock increased 7.87% or $0.28 during the last trading session, reaching $3.84. About 1.32M shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since April 18, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 4 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Achillion Pharmaceuticals had 5 analyst reports since October 23, 2017 according to SRatingsIntel. The stock has “Hold” rating by FBR Capital on Wednesday, February 7. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by Robert W. Baird on Monday, October 23. The stock has “Hold” rating by FBR Capital on Friday, February 23. The rating was maintained by Leerink Swann on Monday, December 11 with “Buy”.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $529.51 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.